After excluding two patients who, r

After excluding two patients who, respectively, received BCGtherapy or platinum-based chemotherapy without RNU, we ana- lyzed 54 UTUC patients for survival. However, no significant differ- ence was observed in prognosis (bladder recurrence-free survival or overall survival) between TERT promoter mutation and wild type (Figure 4A,B). UTUC patients with high MAF of the TERT C228T mu- tation in urinary cfDNA had shorter overall survival than those with low MAF (P = 0.040) (Figure S2A). In contrast, MAF of TERT C228Tmutation was not associated with bladder recurrence-free survival among patients with TERT C228T mutation (P = 0.110) (Figure S2B). There was no association between overall survival and tumor copies in urine in the overall cohort (P = 0.899) (Figure S2C).Of the 12 patients in whom both pre- and post-surgery urinary cfDNA could be analyzed, clearance of ctDNA after RNU was con- firmed in seven (58.3%) patients, but in two patients (16.7%), ctDNA persisted even after RNU (Figure 4C). The patients in whom ctDNA persisted tended to have a worse prognosis for recurrence of non- muscle-invasive urothelial bladder carcinoma compared with those who experienced clearance of ctDNA (P = 0.081) (Figure 4D). In six samples, we also investigated DNA of matched samples from FFPE specimens by ddPCR. We were able to confirm the same genetic sta- tus in the urinary cfDNA, which was consistent with the DNA fromthe FFPE specimens.